1Stanberry LR, Jorgensen DM, Nahmias AJ. Herpes simplex viruses land 2. In: Evand AS, koslow RA, editors. Viral infections of humans:epidemiology and control [M]. 4th ed. New York: plenum.Medical Book Company 1997,pp419-454.
3Nahmias A J, Dannenbarger J, Wickliffe C, et al. Clinical aspects of infection with herpes simplex viruses i and 2[M]. In:The huinum Herpesviruses: An Interdisciplinary persoective (Ed, Nahmias A J,Dowdle WR,Schinazi RF)Elsevier Press,Amsterdam 1980,3-9.
4Burke RL. Contemporary approaches to vaccination against herpes simplex virus[J]. Curt Top Microbiol Immunol 1992,179 : 137-158.
6Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020:construction and evaluation in rodents[J]. J Infect Dis 1988,158:602-613.
7Meignier B,Martin B,Whitley PO,et al. In vivo behavior of genetically engineered herpes smiplex viruses R7017 and R7020. Ⅱ.Studies in immunocompetent and immunosuppressed owl monkeys( Aotus trivirgatus) [J]. J Infect Dis 1990,162:313-321.
8Spector FC,Kem ER,Palmer J,et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs[J]. J Infect Dis 1998,177:1143-1154.
